Membranous glomerulonephritis is a kidney disease where the immune system attacks the tiny filters in your kidneys, causing protein to leak into your urine and potentially leading to kidney damage. Treatment approaches range from supportive care to advanced immunosuppressive therapies, with the choice depending on how severe your condition is and your individual risk factors.

Understanding Treatment Goals and Pathways for Kidney Filter Disease

When membranous glomerulonephritis affects your kidneys, the main aim of treatment is to protect your kidney function, reduce the amount of protein leaking into your urine, and prevent serious complications such as blood clots or kidney failure. Your doctor will work to control the symptoms that come with having too much protein in your urine—such as swelling, high blood pressure, and high cholesterol—while also addressing the underlying immune problem that is causing the disease.^[1]

The treatment plan is highly personalized. It depends on whether your condition is primary (caused by your immune system alone) or secondary (triggered by another health problem such as an infection, cancer, or medication). It also depends on how much protein you are losing, how well your kidneys are working, and what your risk is of developing progressive kidney damage. Some people experience spontaneous remission, meaning their condition improves on its own without aggressive treatment, while others may need strong medications to suppress the immune system.^[2]

Medical societies and kidney specialists have developed guidelines to help doctors decide who needs treatment and what type of treatment is most appropriate. These recommendations are based on years of research, including clinical trials testing different medications and approaches. Today, there are established standard therapies that have been used for decades, as well as newer drugs being tested in clinical trials that may offer better outcomes with fewer side effects.^[4]

Standard Treatment Approaches

The foundation of treatment for membranous glomerulonephritis starts with supportive measures to manage symptoms and protect kidney function. This is sometimes called conservative or symptomatic treatment, and it applies to almost everyone with the condition, regardless of severity.^[5]

A low-sodium diet is key to reducing the swelling that comes from water retention. Your doctor or a dietitian will advise you on how much salt to avoid. Reducing the amount of protein you eat may also be recommended, although this is more controversial and depends on individual circumstances. The goal is to ease the workload on your kidneys without depriving your body of essential nutrients.^[8]

Diuretics are medications that help your body get rid of excess fluid. Loop diuretics, which work on a specific part of the kidney, are the most commonly used type. These medicines help reduce swelling in your legs, feet, and face, and can make breathing easier if fluid has built up in your lungs.^[8]

High blood pressure is a frequent companion of this disease, and controlling it is essential to prevent further kidney damage. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are the preferred medications. These drugs not only lower blood pressure but also reduce the amount of protein leaking into your urine. They work by relaxing blood vessels and reducing pressure inside the kidney filters. If you cannot tolerate ACE inhibitors (for example, if they cause a persistent cough), ARBs are an excellent alternative.^[8]

High cholesterol is another common problem in people with membranous glomerulonephritis. Statins, a class of cholesterol-lowering drugs, are used to treat this. High cholesterol increases the risk of heart disease and stroke, which are more common in people with kidney disease, so keeping cholesterol levels under control is an important part of your overall care.^[8]

People with membranous glomerulonephritis are at increased risk of developing blood clots, particularly in the deep veins of the legs (deep vein thrombosis) or in the lungs (pulmonary embolism). This risk is especially high if your blood albumin level is very low—below 2.8 grams per deciliter, and even more so if it falls below 2.2 grams per deciliter. Some doctors may recommend anticoagulation therapy (blood thinners) to prevent clots, though this decision is individualized. If a clot is found, anticoagulation is generally continued indefinitely.^[8]

For patients who have low risk of progressive kidney disease—meaning their kidney function is stable, they are not losing massive amounts of protein, and they do not have symptoms that are difficult to control—supportive treatment alone may be sufficient. Regular monitoring is essential to watch for any signs that the disease is worsening.^[12]

However, for patients at moderate, high, or very high risk of progressive kidney injury, more aggressive treatment with immunosuppressive medications is usually recommended. These drugs work by dampening the immune system so it stops attacking the kidney filters.^[2]

Corticosteroids, such as prednisolone or prednisone, are powerful anti-inflammatory drugs that suppress the immune system. They are often combined with other immunosuppressive agents. When your kidneys start to recover, the dose of steroids is gradually reduced. Long-term use of steroids can have side effects, including bone thinning (osteoporosis), increased risk of infections, weight gain, mood changes, and elevated blood sugar levels, so doctors monitor patients carefully.^[1]

Alkylating agents, such as cyclophosphamide or chlorambucil, are chemotherapy drugs that have been used for many years to treat membranous glomerulonephritis. They work by killing or slowing the growth of immune cells that are attacking the kidneys. Typically, cyclophosphamide is given in combination with steroids for a period of six months. This combination has been shown to reduce proteinuria and preserve kidney function. However, alkylating agents can cause serious side effects, including increased risk of infections, bladder problems, reduced fertility, and, in the long term, a slightly increased risk of cancer. Because of these risks, they are usually reserved for patients at very high risk of kidney failure.^[8]

Calcineurin inhibitors, such as cyclosporine or tacrolimus, are another class of immunosuppressive drugs. They work by blocking a specific part of the immune system. These drugs can be effective at reducing protein loss and have been used as an alternative to alkylating agents. However, they can cause kidney toxicity, high blood pressure, and other side effects, and the disease often relapses after stopping the medication.^[8]

Currently, rituximab is considered the first-line treatment for many patients with membranous glomerulonephritis. Rituximab is a monoclonal antibody that targets a protein called CD20, which is found on the surface of certain immune cells (B lymphocytes). By depleting these B cells, rituximab helps reduce the production of the antibodies that are attacking the kidney filters. Clinical studies have shown that rituximab is effective at reducing proteinuria and inducing remission, and it has a better safety profile than older chemotherapy drugs. Because of this, the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend rituximab as the preferred immunosuppressive therapy for most patients.^[8]

Treatment with immunosuppressive drugs usually lasts several months. During this time, you will need regular blood tests and check-ups to monitor your kidney function, protein levels, and any side effects from the medications. Your doctor will also check for signs of infection, since suppressing the immune system makes you more vulnerable to infections. Vaccinations, such as the seasonal flu vaccine and the pneumococcal vaccine (which protects against pneumonia), are recommended to reduce your risk.^[18]

Treatment in Clinical Trials

Research into new treatments for membranous glomerulonephritis is ongoing, and several promising therapies are currently being tested in clinical trials. These trials are designed to find safer and more effective ways to control the disease, reduce side effects, and improve long-term outcomes for patients.^[11]

Clinical trials are conducted in phases. Phase I trials test the safety of a new drug in a small group of people, usually healthy volunteers, to find out what dose is safe and what side effects might occur. Phase II trials involve a larger group of patients with the disease and focus on whether the drug works—in other words, whether it reduces proteinuria or improves kidney function. Phase III trials compare the new treatment to the current standard treatment in a large number of patients to see if the new therapy is better, equally effective, or has fewer side effects. Phase IV trials happen after a drug is approved and look at long-term effects and how the drug works in real-world conditions.^[24]

One area of active research is refining the use of rituximab and finding the best dosing schedule. Researchers are also studying how to predict which patients will respond well to rituximab and which patients might need additional or alternative treatments. For example, measuring the levels of anti-PLA2R antibodies in the blood over time can help doctors predict whether a patient is likely to go into remission or whether the disease might relapse. This kind of personalized medicine approach is becoming more common.^[9]

Another focus of clinical trials is finding treatments for patients who do not respond to rituximab. This is sometimes called rituximab-refractory disease. For these patients, researchers are testing other types of immunosuppressive drugs or combinations of drugs. Some studies are exploring drugs that target different parts of the immune system, such as inhibiting specific signaling pathways or blocking the action of certain immune molecules.^[9]

New classes of drugs are also being investigated. For instance, some trials are testing complement inhibitors. The complement system is part of the immune system that helps antibodies and immune cells clear pathogens, but in membranous glomerulonephritis, it can contribute to kidney damage. Drugs that block parts of the complement system may reduce inflammation and kidney injury.^[11]

There is also interest in drugs that target the production of the antibodies themselves. Since the disease is caused by antibodies attacking proteins on the kidney filter, stopping the production of these antibodies could halt the disease process. Researchers are studying drugs that interfere with the signaling pathways that lead to antibody production by B cells and plasma cells.^[11]

Clinical trials are conducted at hospitals and research centers around the world, including in Europe, the United States, and other regions. Eligibility for a clinical trial depends on many factors, including your age, kidney function, the severity of your disease, and whether you have tried other treatments. If you are interested in participating in a clinical trial, your nephrologist can help you find out if there are any trials that might be suitable for you. Participating in a trial gives you access to new treatments that are not yet widely available, and it also contributes to advancing medical knowledge and helping future patients.^[11]

Monitoring and Long-Term Care

Regular follow-up is essential for anyone with membranous glomerulonephritis. Your doctor will monitor your kidney function with blood tests that measure creatinine and estimated glomerular filtration rate (eGFR). Urine tests will check the amount of protein you are losing. Blood pressure, cholesterol levels, and albumin levels will also be checked regularly.^[5]

If your disease progresses despite treatment and your kidneys fail, you may need kidney replacement therapy. This can be in the form of dialysis, a treatment that removes waste products and excess fluid from your blood using a machine, or a kidney transplant, where a healthy kidney from a donor is surgically placed into your body. Both options have their own benefits and challenges, and your healthcare team will discuss which is best for you.^[1]

Lifestyle changes can also help protect your kidneys. Quitting smoking is one of the most important things you can do, as smoking accelerates kidney damage and increases the risk of heart disease and stroke. Maintaining a healthy weight, eating a balanced diet, and staying physically active are all beneficial. Your healthcare team, including dietitians and other specialists, will support you in making these changes.^[5]

Most common treatment methods

• Conservative and Supportive Care
  • Low-sodium diet to reduce swelling and fluid retention
  • Diuretics, especially loop diuretics, to manage edema
  • Protein restriction in some cases to reduce kidney workload
  • Regular monitoring of kidney function, proteinuria, blood pressure, and cholesterol
• Blood Pressure Management
  • ACE inhibitors to lower blood pressure and reduce proteinuria
  • ARBs as an alternative for patients who cannot tolerate ACE inhibitors
• Cholesterol Management
  • Statins to lower cholesterol and reduce risk of cardiovascular complications
• Anticoagulation Therapy
  • Blood thinners to prevent or treat blood clots, especially in patients with very low albumin levels
• Immunosuppressive Therapy
  • Corticosteroids (prednisolone or prednisone) to reduce inflammation and suppress the immune system
  • Cyclophosphamide or chlorambucil (alkylating agents) combined with corticosteroids for patients at very high risk
  • Calcineurin inhibitors (cyclosporine or tacrolimus) as an alternative to alkylating agents
  • Rituximab (anti-CD20 monoclonal antibody), currently considered first-line immunosuppressive therapy
• Treatment of Underlying Causes (Secondary Membranous Glomerulonephritis)
  • Antiviral therapy for hepatitis B or hepatitis C infections
  • Stopping or changing medications that may be causing the disease
  • Treatment of underlying cancers or autoimmune conditions
• Kidney Replacement Therapy
  • Dialysis (hemodialysis or peritoneal dialysis) for end-stage kidney disease
  • Kidney transplantation for eligible patients with kidney failure
• Preventive Measures
  • Vaccinations (flu vaccine and pneumococcal vaccine) to reduce infection risk
  • Smoking cessation to prevent further kidney damage and cardiovascular complications
  • Healthy lifestyle including balanced diet, physical activity, and weight management